The comparison has a naming problem

Sermorelin vs Ipamorelin: check the names in the study

Two mechanisms can cooperate. That does not make every pair in their families a tested combination.

Background

Who signs for it

The comparison ends where the prescription begins

A comparison page can rank mechanisms. It cannot choose treatment: research-labelled peptides remain on sale, a separate route from an individual prescription. A licensed clinician's review is the first step in prescription care. Ipamorelin acetate remains in FDA Category 2 for 503B only; that is not a 503A classification.

At mypromise.com, Promise Peptides currently prescribes sermorelin as care requiring a prescription; a clinician with a U.S. licence reads the patient's history before accepting or declining the request. Promise Peptides considers U.S. patients alone, and its menu of care differs across state lines and between treatments. Each compounded medicine has no FDA approval. That is the honest end of a comparison. The doorways differ; the person who opens one holds a licence. This digest holds none, and picks none.

The synergy experiment used GHRP-2

The tempting evidence for combining growth-hormone signals comes from GHRH and GHRP-2 tested together in men. The combined response exceeded the sum of the separate responses. But GHRP-2 was the second drug tested; ipamorelin was absent from the experiment.

Sermorelin acts through the GHRH receptor. Ipamorelin is in the GHRP class, acting through the ghrelin/GHS receptor, a different control on growth hormone release. That receptor difference explains why combining pathways is a research idea. It does not make the studied pair interchangeable with sermorelin and ipamorelin.

I object to a comparison that swaps the names while preserving the impressive outcome. The family resemblance is scientifically relevant; the substitution is still a substitution. No direct result in this record establishes a preferred sermorelin-ipamorelin combination for an individual’s health.

Visceral fat and IGF-1 in the men’s response

The synergy study involved 47 men aged 18-74 under a sex-steroid clamp. Abdominal visceral fat, IGF-1 and IGFBP-3 jointly explained 60% of variability in the combined response. More visceral fat was negatively associated with the response; IGF-1 was positively associated.

I’m struck by how much the person’s physiology mattered to an experiment often reduced to a combination of drug names. The extra effect varied among participants.

The older men and women studied with GHRP-2 add another distinct observation: continuous administration for 30 days increased pulsatile growth hormone and serum IGF-1 within 24 hours and sustained the elevation, while a low amount of GHRP-2 augmented the response to GHRH 1-44NH2. Again, these are the compounds actually tested. The results concern hormone secretion, not demonstrated long-term wellness benefits.

Sermorelin vs CJC-1295 is also a question of duration

Sermorelin and CJC-1295 are both GHRH-receptor analogs. CJC-1295 with DAC attaches to the blood protein albumin, extending its time in circulation. Native sermorelin has a brief plasma half-life: the intravenous pharmacokinetic study reports about 10-12 minutes, despite growth hormone remaining elevated for about 3 hours.

I don’t award a medicine extra merit for lingering. A longer-lasting signal changes exposure; it does not establish a larger health benefit or a smaller risk. The relevant comparison would follow those outcomes alongside the time on the clock.

The older literature’s interest in longer-acting analogs makes pharmacological sense. It cannot choose the duration of stimulation that best serves an adult’s health.

Sermorelin vs tesamorelin: the outcome cannot change owners

Tesamorelin is a stabilized GHRH analog. Its controlled cognition trial included 152 older adults, 66 with mild cognitive impairment, and ran for 20 weeks. Cognition showed a favorable effect, IGF-1 rose 117% within the physiological range, and percent body fat fell 7.4%.

Those results are a reason to examine tesamorelin. They do not turn into sermorelin memory or fat-loss findings because the drugs share a receptor pathway. Tesamorelin’s FDA approval concerns HIV-associated lipodystrophy, not general anti-aging treatment, and it does not extend to sermorelin.

My preference in a comparison is for a modest conclusion with the correct name attached. The receptor, duration and tested outcome can each differ. Collapsing them into a list of equivalent options removes exactly what made the studies informative.

Direct growth hormone supplies the output

Direct growth hormone treatment supplies growth hormone itself. Sermorelin prompts the pituitary to produce and release it, with feedback controls still influencing the response. Walker’s editorial argues that stimulating endogenous secretion may be a more physiological approach to adult-onset insufficiency.

I give that argument weight as a rationale for investigation. I do not mistake it for a comparative trial proving better health or long-term safety. The cautionary editorial on secretagogues and aging challenges whether the clinical evidence supports the broader use.

A comparison is useful when it tells me why the medicines differ. It becomes less useful when that explanation quietly becomes a treatment choice. The research record supplies the outcomes; the safety record shows how many questions remain.